Summary
3.7785 -0.0715(-1.8571%)09/27/2024
Soligenix Inc (SNGX)
Soligenix Inc (SNGX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -2.1114 | -3.1154 | -1.5811 | 35.9173 | 524.0297 | 605.3388 | 306.2903 | -99.9580 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 3.7785 | |
| Open | 3.8900 | |
| High | 3.8900 | |
| Low | 3.7501 | |
| Volume | 19,740 | |
| Change | -0.0815 | |
| Change % | -2.1114 | |
| Avg Volume (20 Days) | 72,356 | |
| Volume/Avg Volume (20 Days) Ratio | 0.27 | |
| 52 Week Range | 0.30 - 14.83 | |
| Price vs 52 Week High | -74.52% | |
| Price vs 52 Week Low | 1,158.24% | |
| Range | -2.8663 | |
| Gap Up/Down | -0.1500 | |
Fundamentals | ||
| Market Capitalization (Mln) | 9 | |
| EBIDTA | -9,495,876 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -1.5200 | |
| WallStreet Target Price | 4.8800 | |
| Book Value | 0.3530 | |
| Earnings Per Share | -0.3630 | |
| EPS Estimate Current Quarter | -0.1200 | |
| EPS Estimate Next Quarter | -0.1300 | |
| EPS Estimate Current Year | -0.3400 | |
| EPS Estimate Next Year | -0.4800 | |
| Diluted EPS (TTM) | -0.3630 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -16.2233 | |
| Return on asset (TTM) | -0.4103 | |
| Return on equity (TTM) | -1.1921 | |
| Revenue TTM | 869,409 | |
| Revenue per share TTM | 0.0240 | |
| Quarterly Revenue Growth (YOY) | -0.6940 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 538,498 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.1752 | |
| Revenue Enterprise Value | 15.9433 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 42,873,400 | |
| Shares Float | 42,770,542 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.25 | |
| Institutions (%) | 11.24 | |
09/20 09:00 EST - accesswire.com
Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / September 20, 2024 / RedChip Companies will air interviews with Nova Minerals Limited (Nasdaq:NVA) and Soligenix Inc. (Nasdaq:SNGX) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, September 21, at 7 p.m. Eastern Time (ET).
Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / September 20, 2024 / RedChip Companies will air interviews with Nova Minerals Limited (Nasdaq:NVA) and Soligenix Inc. (Nasdaq:SNGX) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, September 21, at 7 p.m. Eastern Time (ET).
09/16 07:30 EST - prnewswire.com
Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024
PRINCETON, N.J. , Sept. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, is pleased to invite investors to a webinar on September 18, 2024, at 4:15 p.m.
Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024
PRINCETON, N.J. , Sept. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, is pleased to invite investors to a webinar on September 18, 2024, at 4:15 p.m.
09/03 07:30 EST - prnewswire.com
Soligenix Receives European Patent for Improved Production of Synthetic Hypericin
Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J. , Sept. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Patent Office has granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin".
Soligenix Receives European Patent for Improved Production of Synthetic Hypericin
Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J. , Sept. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Patent Office has granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin".
08/16 09:00 EST - accesswire.com
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / August 16, 2024 / RedChip Companies will air interviews with Soligenix Inc. (Nasdaq:SNGX) and American Resources Corp. (Nasdaq:AREC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 17, at 7 p.m. Eastern Time (ET).
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / August 16, 2024 / RedChip Companies will air interviews with Soligenix Inc. (Nasdaq:SNGX) and American Resources Corp. (Nasdaq:AREC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 17, at 7 p.m. Eastern Time (ET).
08/09 07:30 EST - prnewswire.com
Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results
PRINCETON, N.J. , Aug. 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2024.
Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results
PRINCETON, N.J. , Aug. 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2024.
07/15 10:16 EST - globenewswire.com
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
07/10 07:12 EST - marketbeat.com
Uncover Why This Pharma Stock Jumped 400% on Study Update
Soligenix Inc. NASDAQ: SNGX, a late-stage biopharmaceutical company, experienced an astonishing surge Tuesday. At the time of writing, the stock had soared nearly 400%.
Uncover Why This Pharma Stock Jumped 400% on Study Update
Soligenix Inc. NASDAQ: SNGX, a late-stage biopharmaceutical company, experienced an astonishing surge Tuesday. At the time of writing, the stock had soared nearly 400%.
07/09 14:37 EST - investorplace.com
5 Investors Betting Big on Soligenix (SNGX) Stock
Shares of Soligenix (NASDAQ: SNGX ) are surging higher by over 300% following an update on the biopharmaceutical company's study of its HyBryte treatment. HyBryte focuses on patients with early-stage cutaneous T-cell lymphoma (CTCL).
5 Investors Betting Big on Soligenix (SNGX) Stock
Shares of Soligenix (NASDAQ: SNGX ) are surging higher by over 300% following an update on the biopharmaceutical company's study of its HyBryte treatment. HyBryte focuses on patients with early-stage cutaneous T-cell lymphoma (CTCL).
07/09 12:11 EST - benzinga.com
Crude Oil Down 1%; Soligenix Shares Surge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 50 points on Tuesday.
Crude Oil Down 1%; Soligenix Shares Surge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 50 points on Tuesday.
07/09 11:38 EST - benzinga.com
Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why
Soligenix Inc SNGX shares surged on Tuesday on a heavy volume of 23.6 million as per data from Benzinga Pro.
Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why
Soligenix Inc SNGX shares surged on Tuesday on a heavy volume of 23.6 million as per data from Benzinga Pro.
07/09 10:04 EST - investorplace.com
Why Is Soligenix (SNGX) Stock Up 296% Today?
Soligenix (NASDAQ: SNGX ) stock is rocketing higher on Tuesday following positive data from the late-stage biopharmaceutical company's extended HyBryte treatment. This data interim data comes from a 12-month study testing HyBryte as a treatment for early-stage cutaneous T-cell lymphoma (CTCL).
Why Is Soligenix (SNGX) Stock Up 296% Today?
Soligenix (NASDAQ: SNGX ) stock is rocketing higher on Tuesday following positive data from the late-stage biopharmaceutical company's extended HyBryte treatment. This data interim data comes from a 12-month study testing HyBryte as a treatment for early-stage cutaneous T-cell lymphoma (CTCL).
07/09 07:30 EST - prnewswire.com
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , July 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL).
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , July 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL).
06/25 07:30 EST - prnewswire.com
Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma
HyBryte™ demonstrates more rapid and robust treatment response compared to Valchlor® during 12-week treatment course PRINCETON, N.J. , June 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive clinical results from a comparability study evaluating HyBryte™ (synthetic hypericin) versus Valchlor® (mechlorethamine gel) in the treatment of cutaneous T-cell lymphoma (CTCL).
Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma
HyBryte™ demonstrates more rapid and robust treatment response compared to Valchlor® during 12-week treatment course PRINCETON, N.J. , June 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive clinical results from a comparability study evaluating HyBryte™ (synthetic hypericin) versus Valchlor® (mechlorethamine gel) in the treatment of cutaneous T-cell lymphoma (CTCL).
06/14 07:30 EST - prnewswire.com
A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
Advanced subunit vaccine technology, including SuVax™ and MarVax™, to be discussed alongside mRNA and viral vectored vaccine approaches PRINCETON, N.J., June 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Professor Axel Lehrer, University of Hawaiʽi at Mānoa (UHM), will be presenting key data from the Company's thermostable vaccine technology platform developed in collaboration with UHM, including results from the filovirus vaccine candidates for both Sudan ebolavirus (SuVax™) and Marburg marburgvirus (MarVax™).
A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
Advanced subunit vaccine technology, including SuVax™ and MarVax™, to be discussed alongside mRNA and viral vectored vaccine approaches PRINCETON, N.J., June 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Professor Axel Lehrer, University of Hawaiʽi at Mānoa (UHM), will be presenting key data from the Company's thermostable vaccine technology platform developed in collaboration with UHM, including results from the filovirus vaccine candidates for both Sudan ebolavirus (SuVax™) and Marburg marburgvirus (MarVax™).
06/07 09:00 EST - accesswire.com
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (Nasdaq:SNGX) and Sharps Technology Inc. (Nasdaq:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET).
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (Nasdaq:SNGX) and Sharps Technology Inc. (Nasdaq:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET).
05/31 07:30 EST - prnewswire.com
Soligenix Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on June 6, 2024 PRINCETON, N.J., May 31, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 16 pre-split shares.
Soligenix Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on June 6, 2024 PRINCETON, N.J., May 31, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 16 pre-split shares.
05/29 07:30 EST - prnewswire.com
Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
Most shareholders can vote by calling 1-833-782-7145 Only one day left to vote PRINCETON, N.J. , May 29, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to vote their shares at the upcoming reconvened meeting on May 30, 2024.
Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
Most shareholders can vote by calling 1-833-782-7145 Only one day left to vote PRINCETON, N.J. , May 29, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to vote their shares at the upcoming reconvened meeting on May 30, 2024.
05/24 07:30 EST - prnewswire.com
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
PRINCETON, N.J. , May 24, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2024 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on May 23, 2024 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission (the "SEC") on April 29, 2024.
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
PRINCETON, N.J. , May 24, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2024 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on May 23, 2024 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission (the "SEC") on April 29, 2024.
05/23 07:30 EST - prnewswire.com
Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split
Most shareholders can vote by calling 1-833-782-7145 PRINCETON, N.J. , May 23, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to vote "FOR" a Reverse Stock Split.
Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split
Most shareholders can vote by calling 1-833-782-7145 PRINCETON, N.J. , May 23, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to vote "FOR" a Reverse Stock Split.
05/21 07:30 EST - prnewswire.com
SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference
PRINCETON, N.J. , May 21, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Professor Axel Lehrer, University of Hawaiʽi at Mānoa (UHM), will be presenting key data from the Company's thermostable vaccine technology platform developed in collaboration with UHM, including results from the filovirus vaccine candidates for both Sudan ebolavirus (SuVax™) and Marburg marburgvirus (MarVax™).
SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference
PRINCETON, N.J. , May 21, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Professor Axel Lehrer, University of Hawaiʽi at Mānoa (UHM), will be presenting key data from the Company's thermostable vaccine technology platform developed in collaboration with UHM, including results from the filovirus vaccine candidates for both Sudan ebolavirus (SuVax™) and Marburg marburgvirus (MarVax™).